Condition
ANCA-Associated Glomerulonephritis
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (1)
P 4 (1)
Trial Status
Unknown1
Recruiting1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07203404Early Phase 1Recruiting
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
NCT07000292Phase 1Not Yet Recruiting
MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
NCT05969522Phase 4Unknown
Stratified Therapy on Pediatric AAGN
Showing all 3 trials